Aridis Pharmaceuticals, Inc.
OTC: ARDS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vu L. Truong
- Employees
- 37
- Headquarters
- Los Gatos, United States
- IPO year
- 2018
- Market cap
- $133.7K
- Website
- https://www.aridispharma.com
Loading ARDS…
Loading profile data…Frequently asked questions about ARDS
What does Aridis Pharmaceuticals, Inc. (ARDS) do?
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase II...
Where does ARDS trade?
Aridis Pharmaceuticals, Inc. (ARDS) trades on the Other OTC.
What sector is ARDS in?
Aridis Pharmaceuticals, Inc. (ARDS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aridis Pharmaceuticals, Inc.?
Vu L. Truong is the chief executive officer of Aridis Pharmaceuticals, Inc. (ARDS).
Where is Aridis Pharmaceuticals, Inc. headquartered?
Aridis Pharmaceuticals, Inc. is headquartered in United States.
Does ARDS pay a dividend?
Aridis Pharmaceuticals, Inc. (ARDS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARDS go public?
Aridis Pharmaceuticals, Inc. (ARDS) completed its initial public offering in 2018.